KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EBIT (2016 - 2025)

Historic EBIT for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $879.9 million.

  • Regeneron Pharmaceuticals' EBIT fell 1113.92% to $879.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.6 billion, marking a year-over-year decrease of 1034.4%. This contributed to the annual value of $3.6 billion for FY2025, which is 1034.4% down from last year.
  • Regeneron Pharmaceuticals' EBIT amounted to $879.9 million in Q4 2025, which was down 1113.92% from $1.0 billion recorded in Q3 2025.
  • Regeneron Pharmaceuticals' EBIT's 5-year high stood at $3.3 billion during Q2 2021, with a 5-year trough of $591.7 million in Q1 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' median EBIT value was $1.1 billion (recorded in 2022), while the average stood at $1.3 billion.
  • Its EBIT has fluctuated over the past 5 years, first soared by 40993.3% in 2021, then crashed by 6684.09% in 2022.
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' EBIT stood at $2.6 billion in 2021, then crashed by 56.56% to $1.1 billion in 2022, then decreased by 15.16% to $972.9 million in 2023, then increased by 1.78% to $990.2 million in 2024, then dropped by 11.14% to $879.9 million in 2025.
  • Its EBIT stands at $879.9 million for Q4 2025, versus $1.0 billion for Q3 2025 and $1.1 billion for Q2 2025.